Tecarfarin

• CAT Number: R029004
• CAS Number: 867257-26-9
• Molecular Formula: C21H14F6O5
• Molecular Weight: 460.33
• Purity: ≥95%
• Synonyms: 4-[(4-Hydroxy-2-oxo-2H-1-benzopyran-3-yl)methyl]benzoic Acid 2,2,2-Trifluoro-1-methyl-1-(trifluoromethyl)ethyl Ester; ATI 5923
• Target: vitamin K epoxide reductase inhibitor
• Storage: -20°C
• IUPAC Name: (1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl) 4-[(4-hydroxy-2-oxochromen-3-yl)methyl]benzoate
• InChI: InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
• InChIKey: QFLNTQDOVCLQKW-UHFFFAOYSA-N
• SMILES: CC(C(F)(F)F)(C(F)(F)F)OC(=O)C1=CC=C(C=C1)CC2=C(C3=CC=CC=C3OC2=O)O

Tecarfarin（Cat No.:R029004）is a novel vitamin K antagonist anticoagulant designed to manage thromboembolic disorders. Unlike warfarin, Tecarfarin is metabolized primarily by esterases, not cytochrome P450 enzymes, reducing the risk of drug-drug interactions and variability in patient response. It offers a more predictable anticoagulation profile, enhancing safety and efficacy in preventing stroke and systemic embolism, particularly in patients with atrial fibrillation or prosthetic heart valves. Tecarfarin represents a significant advancement in anticoagulant therapy, providing a reliable alternative for patients requiring long-term anticoagulation management.